# LITERATURE_REVIEW_AUDIT
Gate 3 audit format version: 2

## Auditor roster
- evidence-provenance perspective: checked whether the Gate 2 record IDs, source caveats, null records, and CLDN18.2 target-selection evidence are sufficient for MVP construction.
- safety-boundary perspective: checked whether the review could be misread as clinical advice, regulatory advice, biosafety clearance, or an executable wet-lab protocol.
- product-evaluation perspective: checked whether the review produces measurable Gate 4 acceptance inputs instead of vague demo-quality aspirations.

## Shared distrust instruction
This literature review and any prior agents or summaries may be wrong, incomplete, hallucinated, or based on a bad read of the domain. Your job is to find what is wrong, what is missing, what is overclaimed, and what must be revised. Verify only from artifacts/tool evidence, cite evidence for every finding, do not advance the project, and return only audit findings.

## Findings by auditor
### Evidence-provenance perspective
- Finding: No Gate 2 rework blocker found for the MVP-construction boundary. The review explicitly says it is not precomputing the CLDN18.2 validation packet and is instead defining product scope, demo target, evidence constraints, and acceptance criteria. Evidence: `LITERATURE_REVIEW.md` "Brief corrections"; `literature-review/FIRST_LOAD.md` "Non-authorization warning".
- Finding: CLDN18.2 selection is acceptable for a demo fixture, but only as a bounded build decision. `CLAIM-001` uses CLDN18.2 clinical/translational maturity, SRC-004 off-tumor safety relevance, ClinicalTrials.gov context, and SRC-016 as a 2025 randomized phase 2 maturity anchor; it also forbids claims of superiority, safety, efficacy, or evidence completeness. Evidence: `DQ-002`, `CLAIM-001`, `CLAIM-006`, `SRC-004`, `SRC-011`, `SRC-016`.
- Finding: Clinical and registry sources remain a misuse risk if Gate 4 does not force context-only labeling. The evidence pack already says ClinicalTrials.gov and PubMed clinical-trial records can be source provenance and translational-status context, not efficacy, safety, or bench-protocol proof. Evidence: `CLAIM-006`, `SRC-002`, `SRC-010`, `SRC-011`, `SRC-016`.

### Safety-boundary perspective
- Finding: No protocol-generation or clinical-advice blocker found in the Gate 2 artifact. The key claims repeatedly restrict output to planning modules, expert-review inputs, caveats, and gap labels. Evidence: `DQ-003`, `DQ-004`, `CLAIM-003`, `CLAIM-009`, `TECH-001`.
- Finding: Gate 4 must test refusal or strong caveating for exact wet-lab parameters, patient-specific treatment advice, regulatory advice, biosafety clearance, and claims that the output is executable or sufficient. Evidence: `DQ-003` forbidden overclaims, `DQ-004` forbidden overclaims, `CLAIM-003` forbidden_overclaim, `CLAIM-009` forbidden_overclaim.
- Finding: CLDN18.2 off-tumor safety is appropriately foregrounded as a caveat, not resolved as safe or unsafe. Evidence: `CLAIM-004`, `SRC-004`, and `LITERATURE_REVIEW.md` "Gaps".

### Product-evaluation perspective
- Finding: Gate 4 can be made measurable from the review, but only if it turns `TECH-001` and `DQ-005` into concrete output checks. Evidence: `TECH-001` defines the packet schema; `DQ-005` requires completeness, citations, record IDs, gap labels, target-selection rationale, fixture determinism, and forbidden-output boundaries.
- Finding: The review correctly treats live retrieval as optional enrichment, not a dependency for the judgeable demo. This is necessary because the retrieval log has recorded API fragility. Evidence: `CLAIM-008`, `NULL-001`, `NULL-002`, `SRC-015`.
- Finding: Source auditability is sufficient for Gate 3 approval because every central claim and DQ points to stable record IDs, but the MVP must render those IDs and caveats visibly. Evidence: `literature-review/MANIFEST.json`, `records/claims.jsonl`, `records/sources.jsonl`, `CLAIM-007`, `DQ-005`.

## Consolidated issues
- CI-001: The Gate 2 literature review is approved-quality for MVP construction, not for direct scientific output packaging. No upstream Gate 2 revision is required.
- CI-002: The main residual risk is downstream misuse: the MVP could accidentally present clinical/trial evidence as bench protocol support, or present qualitative planning modules as executable lab instructions. This is not a Gate 2 blocker because the risk is already identified in `CLAIM-003`, `CLAIM-006`, `CLAIM-009`, and `DQ-005`.
- CI-003: Gate 4 must convert the literature review into acceptance tests. The acceptance tests must cover the complete `TECH-001` section set, source IDs/citations/caveats/gap labels, context-only clinical/trial labeling, deterministic fixture/cache behavior, and forbidden-output refusal or caveating.

## Required revisions or accepted risks
- required_gate2_revisions_before_gate4: none
- accepted_risk: This review is bounded and not a systematic review; it is sufficient for product-design and Gate 4 contract drafting, not sufficient as a final CLDN18.2 validation corpus.
- accepted_risk: Bench-specific cell lines, antigen-density thresholds, assay protocols, control conditions, cytokine panels, and organoid or spheroid model details remain future fixture/content work. They should not be required to approve Gate 2, but the MVP must label such specifics as source-backed or gap-labeled.
- accepted_risk: Clinical/trial records and SRC-016 strengthen demo-target maturity only. They must not be used as evidence that CAR-T validation is solved or that CLDN18.2 is clinically safe/effective for any patient.
- accepted_risk: API live retrieval is fragile under NCBI/Semantic Scholar throttling; the demo should use a deterministic curated fixture/cache and treat live retrieval as optional.

## Gate 4 carry-forward register
#### G4CF-001
- carry_forward_id: G4CF-001
- source_finding_ref: CI-002
- requires_gate4_handling: yes
- gate4_handling_type: automated_evaluation
- required_gate4_section: ## Automated evaluation criteria
- summary: Clinical and trial sources must be labeled context-only and must not support bench-protocol, efficacy, safety, or patient-treatment claims.
- gate4_instruction: Add an automated or mechanically checkable criterion that verifies trial/clinical records including SRC-002, SRC-011, and SRC-016 are displayed as context-only and never used as bench-method proof.

#### G4CF-002
- carry_forward_id: G4CF-002
- source_finding_ref: CI-002
- requires_gate4_handling: yes
- gate4_handling_type: falsification_condition
- required_gate4_section: ## Failure or falsification conditions
- summary: Protocol-like or patient-specific outputs must fail the MVP evaluation.
- gate4_instruction: Define falsification cases for exact wet-lab parameters, executable protocol steps, patient-specific treatment advice, regulatory advice, biosafety clearance, and claims that TargetBench output is sufficient without expert review.

#### G4CF-003
- carry_forward_id: G4CF-003
- source_finding_ref: CI-003
- requires_gate4_handling: yes
- gate4_handling_type: evaluation_approach
- required_gate4_section: ## Evaluation approach
- summary: The judgeable demo must be deterministic from a curated CLDN18.2 fixture/cache because live retrieval had recorded throttling/null events.
- gate4_instruction: Make the core evaluation run against the curated fixture/cache, with any live retrieval treated as optional enrichment and failure-tolerant behavior documented.

#### G4CF-004
- carry_forward_id: G4CF-004
- source_finding_ref: CI-003
- requires_gate4_handling: yes
- gate4_handling_type: success_condition
- required_gate4_section: ## Success conditions
- summary: The MVP output must cover all TECH-001 sections and make provenance/gaps visible.
- gate4_instruction: Require the output to include target rationale, expression/off-tumor screen, model-system suggestions, assay modules, controls, readouts, safety gaps, go/no-go gates, source IDs/citations, caveats, and gap labels.
